<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2019-4-33(408)-48-53</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-1393</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Заболевания щитовидной железы в пери- и постменопаузе (обзор литературы)</article-title><trans-title-group xml:lang="en"><trans-title>Thyroid disease in peri‑ and postmenopause period (literature review)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зайдиева</surname><given-names>Я. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Zaidieva</surname><given-names>Ya. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., проф., рук. отделения гинекологической эндокринологии</p><p>г. Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глазкова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Glazkova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>м. н. с., отделение гинекологической эндокринологии</p><p>г. Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кручинина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kruchinina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>н. с., отделение гинекологической эндокринологии </p><p>г. Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Regional Research Institute for Obstetrics and Gynecology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>23</day><month>01</month><year>2020</year></pub-date><volume>4</volume><issue>33</issue><issue-title>Современная гинекология</issue-title><fpage>48</fpage><lpage>53</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зайдиева Я.З., Глазкова А.В., Кручинина Е.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Зайдиева Я.З., Глазкова А.В., Кручинина Е.В.</copyright-holder><copyright-holder xml:lang="en">Zaidieva Y.Z., Glazkova A.V., Kruchinina E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/1393">https://www.med-alphabet.com/jour/article/view/1393</self-uri><abstract><p>Во время пери‑ и постменопаузы результаты исследований функции щитовидной железы должны интерпретироваться очень внимательно в связи с физиологическими изменениями секреции и метаболизма тиреотропного гормона и гормонов щитовидной железы. У женщин в постменопаузе увеличивается частота заболеваний щитовидной железы. Нет единого мнения в отношении обследования женщин в постменопаузе, хотя имеются данные о влиянии тиреоидного статуса на когнитивные функции, сердечно‑сосудистый риск, метаболизм костной ткани и продолжительность жизни. Постановка диагноза при любом заболевании щитовидной железы является сложной задачей у пожилых пациенток, так как симптомы схожи с менопаузальными. Лечение требует большего внимания в этой популяции, чем у молодых пациенток, так как высокие дозы L‑тироксина могут приводить к сердечно‑сосудистым осложнениям и увеличению скорости костного ремоделирования. Кроме того, радиоактивный йод является предпочтительным в лечении гипертиреоза у пожилых пациентов. В этой группе повышен риск развития узловых заболеваний и рака щитовидной железы. Риск оперативного лечения выше, а прогноз заболеваний хуже. Решение о необходимости применения менопаузальной гормональной терапии должно быть принято индивидуально независимо от наличия заболеваний щитовидной железы.</p></abstract><trans-abstract xml:lang="en"><p>The interpretation of thyroid function tests should be cautiously made during the perimenopause and postmenopause period bearing in mind that physiologic changes do exist in this group of women in terms of secretion and metabolism of thyrotropin and thyroid hormones. Moreover the incidence of thyroid disorders increases in postmenopausal and elderly women. There is no consensus for screening postmenopausal women even though there is well‑known evidence about the effect of thyroid status on cognitive function, cardiovascular risk, bone turnover, and longevity. The diagnosis of any thyroid disorder is challenging in these patients because the symptoms are more subtle and attributed to menopausal symptoms. Management requires more attention in this population than that of younger groups, because high doses of L‑thyroxine can lead to cardiac complications and increased bone turnover. Furthermore radio‑iodine is preferred in treatment of hyperthyroidism in older patients. The risk of nodular thyroid disease and thyroid cancers increases in this group. Although the diagnostic approach is the same as for young patients, the risk of surgery is high and disease prognosis is worse. Decision for menopausal hormonal therapy should be individualized regardless of the concomitant presence of thyroid disorders.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гипотиреоз</kwd><kwd>гипертиреоз</kwd><kwd>рак щитовидной железы</kwd><kwd>менопауза</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypothyroidism</kwd><kwd>hyperthyroidism</kwd><kwd>thyroid</kwd><kwd>cancer</kwd><kwd>menopause</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">del Ghianda S, Tonacchera M, Vitti P. Thyroid and menopause. Climacteric 2014; 17: 225–34.</mixed-citation><mixed-citation xml:lang="en">del Ghianda S, Tonacchera M, Vitti P. Thyroid and menopause. Climacteric 2014; 17: 225–34.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Santin AP, Furlanetto TW. Role of estrogen in thyroid function and growth regulation. J Thyroid Res 2011; 2011: 1.</mixed-citation><mixed-citation xml:lang="en">Santin AP, Furlanetto TW. Role of estrogen in thyroid function and growth regulation. J Thyroid Res 2011; 2011: 1.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001; 344: 1743–9.</mixed-citation><mixed-citation xml:lang="en">Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001; 344: 1743–9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489–99.</mixed-citation><mixed-citation xml:lang="en">Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489–99.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Papaleontiou M, Haymart MR. Approach to and treatment of thyroid disorders in the elderly. Med Clin North Am 2012; 96: 297–310.</mixed-citation><mixed-citation xml:lang="en">Papaleontiou M, Haymart MR. Approach to and treatment of thyroid disorders in the elderly. Med Clin North Am 2012; 96: 297–310.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Volzke H, Alte D, Kohlmann T, Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid 2005; 15: 279–85.</mixed-citation><mixed-citation xml:lang="en">Volzke H, Alte D, Kohlmann T, Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid 2005; 15: 279–85.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007; 92: 4575–82.</mixed-citation><mixed-citation xml:lang="en">Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007; 92: 4575–82.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Boucai L, Hollowell JG, Surks MI. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits.Thyroid 2011; 21: 5–11.</mixed-citation><mixed-citation xml:lang="en">Boucai L, Hollowell JG, Surks MI. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits.Thyroid 2011; 21: 5–11.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wong ET, Bradley SG, Schultz AL. Elevations of thyroid-stimulating hormone during acute nonthyroidal illness. Arch Intern Med 1981; 141: 873–5.</mixed-citation><mixed-citation xml:lang="en">Wong ET, Bradley SG, Schultz AL. Elevations of thyroid-stimulating hormone during acute nonthyroidal illness. Arch Intern Med 1981; 141: 873–5.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Peeters RP, Wouters PJ, Kaptein E, et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003; 88: 3202–11.</mixed-citation><mixed-citation xml:lang="en">Peeters RP, Wouters PJ, Kaptein E, et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003; 88: 3202–11.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Abdullatif HD, Ashraf AP. Reversible subclinical hypothyroidism in the presence of adrenal insufficiency. Endocr Pract 2006; 12: 572.</mixed-citation><mixed-citation xml:lang="en">Abdullatif HD, Ashraf AP. Reversible subclinical hypothyroidism in the presence of adrenal insufficiency. Endocr Pract 2006; 12: 572.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Caufriez A, Leproult R, L’Hermite-Bal_eriaux M. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. J Clin Endocrinol Metab 2011; 96: E 614–23.</mixed-citation><mixed-citation xml:lang="en">Caufriez A, Leproult R, L’Hermite-Bal_eriaux M. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. J Clin Endocrinol Metab 2011; 96: E 614–23.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez-Rodriguez LA, Felici-Giovanini ME, Haddock L. Thyroid dysfunction in an adult female population: a population-based study of Latin American Vertebral Osteoporosis Study (LAVOS) — Puerto Rico site. P R Health Sci J 2013; 32: 57–62.</mixed-citation><mixed-citation xml:lang="en">Gonzalez-Rodriguez LA, Felici-Giovanini ME, Haddock L. Thyroid dysfunction in an adult female population: a population-based study of Latin American Vertebral Osteoporosis Study (LAVOS) — Puerto Rico site. P R Health Sci J 2013; 32: 57–62.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">De Carvalho GA, Bahls SC, Boeving A, Graf H. Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function. Thyroid 2009; 19: 691–7.</mixed-citation><mixed-citation xml:lang="en">De Carvalho GA, Bahls SC, Boeving A, Graf H. Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function. Thyroid 2009; 19: 691–7.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gitlin M, Altshuler LL, Frye MA, et al. Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors.J Psychiatry Neurosci 2004; 29: 383–6.</mixed-citation><mixed-citation xml:lang="en">Gitlin M, Altshuler LL, Frye MA, et al. Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors.J Psychiatry Neurosci 2004; 29: 383–6.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Clonidine and Hypothyroidism — from FDA reports. July 30, 2018. Available from: www.ehealthme.com/ds/clonidine/hypothyroidism.</mixed-citation><mixed-citation xml:lang="en">Clonidine and Hypothyroidism — from FDA reports. July 30, 2018. Available from: www.ehealthme.com/ds/clonidine/hypothyroidism.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Helfand M, Redfern C. C. Screening for thyroid disease: an update. Ann Intern Med 1998; 129: 144–58.</mixed-citation><mixed-citation xml:lang="en">Helfand M, Redfern C. C. Screening for thyroid disease: an update. Ann Intern Med 1998; 129: 144–58.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">American Academy of Family Physicians: Summary of policy recommendations for periodic health examinations, Leawood, KS, 2002, American Academy of Family Physicians.</mixed-citation><mixed-citation xml:lang="en">American Academy of Family Physicians: Summary of policy recommendations for periodic health examinations, Leawood, KS, 2002, American Academy of Family Physicians.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Garber JR, Cobin RH, Gharib H. Clinical practice guidelines for hypothyroidism in adults. Endocr Pract 2012; 18: 988–1028.</mixed-citation><mixed-citation xml:lang="en">Garber JR, Cobin RH, Gharib H. Clinical practice guidelines for hypothyroidism in adults. Endocr Pract 2012; 18: 988–1028.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Rugge JB, Bougatsos C, Chou R. Screening and treatment of thyroid dysfunction: an evidence review for the U. S. Preventive Services Task Force. Ann Intern Med 2015; 162: 35–45.</mixed-citation><mixed-citation xml:lang="en">Rugge JB, Bougatsos C, Chou R. Screening and treatment of thyroid dysfunction: an evidence review for the U. S. Preventive Services Task Force. Ann Intern Med 2015; 162: 35–45.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Stone MB, Wallace RB, Institute of Medicine (U.S.) Committee on Medicare Coverage of Routine Thyroid Screening: Medicare coverage of routine screening for thyroid dysfunction, Washington, DC: National Academies Press 2003.</mixed-citation><mixed-citation xml:lang="en">Stone MB, Wallace RB, Institute of Medicine (U.S.) Committee on Medicare Coverage of Routine Thyroid Screening: Medicare coverage of routine screening for thyroid dysfunction, Washington, DC: National Academies Press 2003.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado Thyroid Disease Prevalence Study. Arch Intern Med 2000; 160: 526–34.</mixed-citation><mixed-citation xml:lang="en">Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado Thyroid Disease Prevalence Study. Arch Intern Med 2000; 160: 526–34.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379: 1142–54.</mixed-citation><mixed-citation xml:lang="en">Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379: 1142–54.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Andersson M, de Benoist B, Delange F, Zupan J. Prevention and control of iodine deficiency in pregnant and lactating women andin children less than 2-years-old: conclusions and recommendations of the Technical Consultation. Phn 2007; 10: 1606–11.</mixed-citation><mixed-citation xml:lang="en">Andersson M, de Benoist B, Delange F, Zupan J. Prevention and control of iodine deficiency in pregnant and lactating women andin children less than 2-years-old: conclusions and recommendations of the Technical Consultation. Phn 2007; 10: 1606–11.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kappers MH, van Esch JH, Smedts FM, de Krijger RR, et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab 2011; 96: 3087–94.</mixed-citation><mixed-citation xml:lang="en">Kappers MH, van Esch JH, Smedts FM, de Krijger RR, et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab 2011; 96: 3087–94.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Huang SA, Fish SA, Dorfman DM, et al. A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J Clin Endocrinol Metab 2002; 87: 4457–61.</mixed-citation><mixed-citation xml:lang="en">Huang SA, Fish SA, Dorfman DM, et al. A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J Clin Endocrinol Metab 2002; 87: 4457–61.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Mouat F, Evans HM, Cutfield WS, Hofman PL, Jefferies C. Massive hepatic hemangioendothelioma and consumptive hypothyroidism. J Pediatr Endocrinol Metab 2008; 21: 701–3.</mixed-citation><mixed-citation xml:lang="en">Mouat F, Evans HM, Cutfield WS, Hofman PL, Jefferies C. Massive hepatic hemangioendothelioma and consumptive hypothyroidism. J Pediatr Endocrinol Metab 2008; 21: 701–3.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Razvi S, Weaver J, Butler T, Pearce S. (Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med 2012; 172: 811–7.</mixed-citation><mixed-citation xml:lang="en">Razvi S, Weaver J, Butler T, Pearce S. (Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med 2012; 172: 811–7.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004; 292: 2591–9.</mixed-citation><mixed-citation xml:lang="en">Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004; 292: 2591–9.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Rozing MP, Houwing-Duistermaat JJ, Slagboom PE, et al. Familial longevity is associated with decreased thyroid function. J Clin Endocrinol Metab 2010; 95: 4979–84.</mixed-citation><mixed-citation xml:lang="en">Rozing MP, Houwing-Duistermaat JJ, Slagboom PE, et al. Familial longevity is associated with decreased thyroid function. J Clin Endocrinol Metab 2010; 95: 4979–84.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: management of subclinical hypothyroidism. Eur Thyroid J 2013; 2: 215–28.</mixed-citation><mixed-citation xml:lang="en">Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: management of subclinical hypothyroidism. Eur Thyroid J 2013; 2: 215–28.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Brent GA. Clinical practice. Graves’ disease. N Engl J Med 2008; 358: 2594.</mixed-citation><mixed-citation xml:lang="en">Brent GA. Clinical practice. Graves’ disease. N Engl J Med 2008; 358: 2594.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 2014; 99: 923–31.</mixed-citation><mixed-citation xml:lang="en">Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 2014; 99: 923–31.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Schouten BJ, Brownlie BE, Frampton CM, Turner JG. Subclinical thyrotoxicosis in an outpatient population — predictors of outcome. Clin Endocrinol (Oxf) 2011; 74: 257–61.</mixed-citation><mixed-citation xml:lang="en">Schouten BJ, Brownlie BE, Frampton CM, Turner JG. Subclinical thyrotoxicosis in an outpatient population — predictors of outcome. Clin Endocrinol (Oxf) 2011; 74: 257–61.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011; 96: E 1–8.</mixed-citation><mixed-citation xml:lang="en">Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011; 96: E 1–8.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin Endocrinol (Oxf) 2010; 72: 685–8.</mixed-citation><mixed-citation xml:lang="en">Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin Endocrinol (Oxf) 2010; 72: 685–8.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Das G, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Okosieme OE. Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol (Oxf) 2012; 77: 146–51.</mixed-citation><mixed-citation xml:lang="en">Das G, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Okosieme OE. Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol (Oxf) 2012; 77: 146–51.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010; 95: 2715.</mixed-citation><mixed-citation xml:lang="en">Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010; 95: 2715.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011; 17: 456–520.</mixed-citation><mixed-citation xml:lang="en">Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011; 17: 456–520.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Faggiano A, Del Prete M, Marciello F, et al. Thyroid diseases in elderly. Minerva Endocrinol 2011; 36: 211–31.</mixed-citation><mixed-citation xml:lang="en">Faggiano A, Del Prete M, Marciello F, et al. Thyroid diseases in elderly. Minerva Endocrinol 2011; 36: 211–31.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Mitrou P, Raptis SA, Dimitriadis G. Thyroid disease in older people. Maturitas 2011; 70: 5–9.</mixed-citation><mixed-citation xml:lang="en">Mitrou P, Raptis SA, Dimitriadis G. Thyroid disease in older people. Maturitas 2011; 70: 5–9.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Asvold BO, Bjoro T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin Endocrinol (Oxf) 2012; 77: 911–7.</mixed-citation><mixed-citation xml:lang="en">Asvold BO, Bjoro T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin Endocrinol (Oxf) 2012; 77: 911–7.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172: 799–809.</mixed-citation><mixed-citation xml:lang="en">Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172: 799–809.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Yang LB, Jiang DQ, Qi WB, et al. Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. Eur J Endocrinol 2012; 167: 75–84.</mixed-citation><mixed-citation xml:lang="en">Yang LB, Jiang DQ, Qi WB, et al. Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. Eur J Endocrinol 2012; 167: 75–84.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126: 1040–9.</mixed-citation><mixed-citation xml:lang="en">Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126: 1040–9.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 2012; 345: e7895.</mixed-citation><mixed-citation xml:lang="en">Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 2012; 345: e7895.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Schultz M, Kistorp C, Raymond I, et al. Cardiovascular events in thyroid disease: a population based, prospective study. Horm Metab Res 2011; 43: 653–9.</mixed-citation><mixed-citation xml:lang="en">Schultz M, Kistorp C, Raymond I, et al. Cardiovascular events in thyroid disease: a population based, prospective study. Horm Metab Res 2011; 43: 653–9.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Chaker L, Baumgartner C, Ikram MA, et al. Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. Eur J Epidemiol 2014; 29: 791–800.</mixed-citation><mixed-citation xml:lang="en">Chaker L, Baumgartner C, Ikram MA, et al. Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. Eur J Epidemiol 2014; 29: 791–800.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Abrahamsen B, Jorgensen HL, Laulund AS, et al. Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures — the OPENTHYRO register cohort. J Bone Miner Res 2014; 29: 2040–50.</mixed-citation><mixed-citation xml:lang="en">Abrahamsen B, Jorgensen HL, Laulund AS, et al. Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures — the OPENTHYRO register cohort. J Bone Miner Res 2014; 29: 2040–50.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Gan EH, Pearce SH. Clinical review: the thyroid in mind: cognitive function and low thyrotropin in older people. J Clin Endocrinol Metab 2012; 97: 3438–49.</mixed-citation><mixed-citation xml:lang="en">Gan EH, Pearce SH. Clinical review: the thyroid in mind: cognitive function and low thyrotropin in older people. J Clin Endocrinol Metab 2012; 97: 3438–49.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Wijsman LW, de Craen AJ, Trompet S, et al. Subclinical thyroid dysfunction and cognitive decline in old age. PLoS One 2013; 8: e59199.</mixed-citation><mixed-citation xml:lang="en">Wijsman LW, de Craen AJ, Trompet S, et al. Subclinical thyroid dysfunction and cognitive decline in old age. PLoS One 2013; 8: e59199.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Formiga F, Ferrer A, Padros G, et al. Thyroid status and functional and cognitive status at baseline and survival after 3 years of follow-up: the OCTABAIX study. Eur J Endocrinol 2014; 170: 69–75.</mixed-citation><mixed-citation xml:lang="en">Formiga F, Ferrer A, Padros G, et al. Thyroid status and functional and cognitive status at baseline and survival after 3 years of follow-up: the OCTABAIX study. Eur J Endocrinol 2014; 170: 69–75.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Roberts LM, Pattison H, Roalfe A, et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 2006; 145: 573–81.</mixed-citation><mixed-citation xml:lang="en">Roberts LM, Pattison H, Roalfe A, et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 2006; 145: 573–81.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Almeida OP, Alfonso H, Flicker L, et al. Thyroid hormones and depression: the Health in Men study. Am J Geriatr Psychiatry 2011; 19: 763–70.</mixed-citation><mixed-citation xml:lang="en">Almeida OP, Alfonso H, Flicker L, et al. Thyroid hormones and depression: the Health in Men study. Am J Geriatr Psychiatry 2011; 19: 763–70.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">de Jongh RT, Lips P, van Schoor NM, et al. Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. Eur J Endocrinol 2011; 165: 545–54.</mixed-citation><mixed-citation xml:lang="en">de Jongh RT, Lips P, van Schoor NM, et al. Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. Eur J Endocrinol 2011; 165: 545–54.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Biondi B, Bartalena L, Cooper DS, et al. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J 2015; 4: 149–63.</mixed-citation><mixed-citation xml:lang="en">Biondi B, Bartalena L, Cooper DS, et al. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J 2015; 4: 149–63.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1–133.</mixed-citation><mixed-citation xml:lang="en">Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1–133.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest 2009; 39: 699–706.</mixed-citation><mixed-citation xml:lang="en">Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest 2009; 39: 699–706.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008; 93: 809–14.</mixed-citation><mixed-citation xml:lang="en">Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008; 93: 809–14.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology 2011; 260: 892–9.</mixed-citation><mixed-citation xml:lang="en">Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology 2011; 260: 892–9.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation-multicenter retrospective study. Radiology 2008; 247: 762–70.</mixed-citation><mixed-citation xml:lang="en">Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation-multicenter retrospective study. Radiology 2008; 247: 762–70.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Moon HJ, Kwak JY, Kim MJ, Son EJ, Kim EK. Can vascularity at power Doppler US help predict thyroid malignancy? Radiology 2010; 255: 260–9.</mixed-citation><mixed-citation xml:lang="en">Moon HJ, Kwak JY, Kim MJ, Son EJ, Kim EK. Can vascularity at power Doppler US help predict thyroid malignancy? Radiology 2010; 255: 260–9.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Salmaslıoglu A, Erbil Y, Dural C, et al. Predictive value of sonographic features in preoperative evaluation of malignant thyroid nodules in a multinodular goiter. World J Surg 2008; 32: 1948–54.</mixed-citation><mixed-citation xml:lang="en">Salmaslıoglu A, Erbil Y, Dural C, et al. Predictive value of sonographic features in preoperative evaluation of malignant thyroid nodules in a multinodular goiter. World J Surg 2008; 32: 1948–54.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Gul K, Ersoy R, Dirikoc A, et al. Ultrasonographic evaluation of thyroid nodules: comparison of ultrasonographic, cytological, and histopathological findings. Endocrine 2009; 36: 464–72.</mixed-citation><mixed-citation xml:lang="en">Gul K, Ersoy R, Dirikoc A, et al. Ultrasonographic evaluation of thyroid nodules: comparison of ultrasonographic, cytological, and histopathological findings. Endocrine 2009; 36: 464–72.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Gervasi R, Orlando G, Lerose MA, et al. Thyroid surgery in geriatric patients: a literature review. BMC Surg 2012; 12: S 16–S 518.</mixed-citation><mixed-citation xml:lang="en">Gervasi R, Orlando G, Lerose MA, et al. Thyroid surgery in geriatric patients: a literature review. BMC Surg 2012; 12: S 16–S 518.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Uygur MM., Yoldemir T., Yavuz DG. Thyroid disease in the perimenopause and postmenopause period Climacteric, 2018; 21: 6: 542–548.</mixed-citation><mixed-citation xml:lang="en">Uygur MM., Yoldemir T., Yavuz DG. Thyroid disease in the perimenopause and postmenopause period Climacteric, 2018; 21: 6: 542–548.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
